{"disease":{"id":"glucosylceramide-beta-glucosidase-deficiency","name":"Glucosylceramide beta-glucosidase deficiency","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"imiglucerase","indication_name":"Glucosylceramide beta-glucosidase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cerezyme","generic_name":"IMIGLUCERASE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC]","quality_score":40,"revenue":"800","mechanism":"Cerezyme replaces the deficient enzyme in patients with Gaucher disease, allowing for the breakdown of glucocerebroside."},{"drug_id":"eliglustat","indication_name":"Glucosylceramide beta-glucosidase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cerdelga","generic_name":"ELIGLUSTAT","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Ceramide glucosyltransferase","drug_class":"Glucosylceramide Synthase Inhibitor [EPC]","quality_score":66,"revenue":"400","mechanism":"Cerdelga works by inhibiting the enzyme ceramide glucosyltransferase, which is involved in the production of glucosylceramide."},{"drug_id":"voglibose","indication_name":"Glucosylceramide beta-glucosidase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glustat","generic_name":"VOGLIBOSE","company_name":"","drug_phase":"marketed","molecular_target":"Lysosomal alpha-glucosidase","drug_class":"voglibose","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"miglustat","indication_name":"Glucosylceramide beta-glucosidase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavesca","generic_name":"MIGLUSTAT","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Lysosomal alpha-glucosidase","drug_class":"Glucosylceramide Synthase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Zavesca works by inhibiting the enzyme glucosylceramide synthase, which is involved in the production of a toxic lipid that accumulates in cells of patients with certain lysosomal storage disorders."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00358943","title":"International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}